Seres Therapeutics has been granted a patent for a therapeutic composition containing non-pathogenic bacterial spores for the prevention, control, and treatment of gastrointestinal diseases. The patent also includes a method of treating Clostridium difficile infection (CDI) by administering an oral therapeutic composition containing spore-forming bacteria. GlobalData’s report on Seres Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Seres Therapeutics, Microbiota restoration therapy was a key innovation area identified from patents. Seres Therapeutics's grant share as of September 2023 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of gastrointestinal diseases with non-pathogenic bacterial spores
A recently granted patent (Publication Number: US11730775B2) describes a method for treating Clostridium difficile infection (CDI) or its symptoms in a subject. The method involves administering a therapeutic composition orally to the subject. The composition consists of a purified population of spore-forming bacteria in the form of spores and is encapsulated in a capsule.
The patent claims that the therapeutic composition can effectively treat CDI or its symptoms. It also states that at least one type of spore-forming bacteria in the composition is not detectably present in the gastrointestinal tract of the subject before administration. Administering the composition can result in the growth of bacteria that were not initially present in the composition or the gastrointestinal tract. Additionally, the composition can lead to the reduction or elimination of pathogens and/or pathobionts in the gastrointestinal tract, engraftment of spore-forming bacteria from the composition in the gastrointestinal tract, and augmentation of spore-forming or non-spore forming bacteria that are not present in the composition.
The method is suitable for adult subjects who have received antibiotic therapy. The therapeutic composition can be administered 1, 2, or 3 days after completing antibiotic treatment. The composition contains a range of spore colony-forming units of the spore-forming bacteria per dose, from about 1×104 to about 1×1015. Antibiotics are not administered concurrently with the therapeutic composition.
The therapeutic composition may also include glycerol and saline. It is administered once daily on an empty stomach for a duration of 3 days. Prior to administration, the subject may undergo a colon-cleansing preparation.
In addition to treating CDI, the patent also claims a method for reducing the recurrence of CDI or its symptoms. The administration of the therapeutic composition can effectively reduce the recurrence of CDI or its symptoms in the subject.
Overall, this granted patent describes a method for treating and reducing the recurrence of Clostridium difficile infection using a therapeutic composition containing spore-forming bacteria. The method offers potential benefits in the management of CDI and its symptoms, particularly in adult patients who have undergone antibiotic therapy.
To know more about GlobalData’s detailed insights on Seres Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
